Molecular Mechanisms of Immune Evasion and Host Manipulation by Trichomonas vaginalis: A Comprehensive Paradigm Shift

المؤلفون

DOI:

https://doi.org/10.64554/nujms.2026.2.2.4

الكلمات المفتاحية:

Complement System Proteins، Extracellular Traps، Extracellular Vesicles، Immune Evasion، Trichomonas vaginalis، Trichomonas Infections، Mycoplasma hominis، HostParasite Interactions

الملخص

Abstract

Background: Trichomoniasis, caused by the flagellated protozoan Trichomonas vaginalis, is the most common curable non-viral sexually transmitted infection worldwide. Most infections produce no symptoms, yet they are linked to adverse pregnancy outcomes, a higher risk of acquiring human immunodeficiency virus and an association with cervical neoplasia. Objective: To review how T. vaginalis interacts with, and may evade, innate and adaptive immune defenses, and to grade the strength of the evidence behind each proposed mechanism. Methods: Narrative review of the literature indexed in PubMed. Studies were classified by experimental model (human, murine or parasite-only systems) and by the level of mechanistic support. Results: The best-supported mechanisms are acquisition of a host membrane regulator of complement, which reduces complementmediated lysis in vitro; induction of neutrophil extracellular traps by parasite surface glycoconjugates; contact-dependent killing of the parasite by neutrophils through trogocytosis; and activation of inflammatory signaling in macrophages and epithelial cells by the parasite and its extracellular vesicles. The roles of parasite cysteine proteases, surface antigenic variation, Mycoplasma hominis and Trichomonas vaginalis virus are biologically plausible but less firmly established. Much of the mechanistic evidence comes from in vitro and murine systems, and several proposed pathways, including epigenetic reprogramming of host cells, remain untested.  Conclusions: Persistence of T. vaginalis is best understood as a network of overlapping, partly redundant interactions, not a single evasion program. Priorities are validation in primary human mucosal models, strain-resolved studies, and tests of whether these mechanisms explain treatment failure and clinical sequelae. 

التنزيلات

تنزيل البيانات ليس متاحًا بعد.

المراجع

1. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548–62. doi:10.2471/BLT.18.228486.

2. WHO. Trichomoniasis [Internet]. 2025 [cited 2026 Jun 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/trichomoniasis

3. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis. 2007;45(10):1319–26. doi:10.1086/522532.

4. Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307. doi:10.1186/s12879-015-1055-0.

5. Javanbakht M, Stirland A, Stahlman S, et al. Prevalence and factors associated with Trichomonas vaginalis infection among high-risk women in Los Angeles. Sex Transm Dis. 2013 Oct;40(10):804–7. doi:10.1097/OLQ.0000000000000026.

6. Van Gerwen OT, Craig-Kuhn MC, Jones AT, et al. Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis. BJOG. 2021;128(12):1907–15. doi:10.1111/1471-0528.16774.

7. Masha SC, Cools P, Sanders EJ, et al. Trichomonas vaginalis and HIV infection acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2019;95(1):3642. doi:10.1136/sextrans-2018-053713.

8. Fazlollahpour-Naghibi A, Bagheri K, Almukhtar M, et al. Trichomonas vaginalis infection and risk of cervical neoplasia: a systematic review and meta-analysis. PLoS One. 2023;18(7):e0288443. doi:10.1371/journal.pone.0288443.

9. Hamar B, Teutsch B, Hoffmann E, et al. Trichomonas vaginalis infection is associated with increased risk of cervical carcinogenesis: a systematic review and meta-analysis of 470 000 patients. Int J Gynaecol Obstet. 2023;163(1):31–43. doi:10.1002/ijgo.14763.

10. Najafi A, Chaechi Nosrati MR, Ghasemi E, et al. Is there association between Trichomonas vaginalis infection and prostate cancer risk? A systematic review and meta-analysis. Microb Pathog. 2019;137:103752. doi:10.1016/j.micpath.2019.103752.

11. Ryan CM, de Miguel N, Johnson PJ. Trichomonas vaginalis: current understanding of host–parasite interactions. the Essays Biochem. 2011;51(1):161–75. doi:10.1042/BSE0510161.

12. Shiratori M, Patel A, Gerhold RW, et al. Persistent Trichomonas vaginalis infections and pseudocyst form. Trends Parasitol. 2023;39(12):1023–31. doi:10.1016/j.pt.2023.09.009.

13. Beri D, Yadav P, Devi HRN, et al. Demonstration and characterization of cyst-like structures in the life cycle of Trichomonas vaginalis. Front Cell Infect Microbiol. 2020;9:430. doi:10.3389/fcimb.2019.00430.

14. Makki A, Kereïche S, Le T, et al. A hybrid TIM complex mediates protein import into hydrogenosomes of Trichomonas vaginalis. BMC Biol. 2024;22(1):130. doi:10.1186/s12915-024-01928-8.

15. Rendón-Gandarilla FJ, Ramón-Luing Lde L, Ortega-López J, et al. The TvLEGU-1, a legumain-like cysteine proteinase, plays a key role in Trichomonas vaginalis cytoadherence. Biomed Res Int. 2013;2013:561979. doi:10.1155/2013/561979.

16. Henderson B, Fares MA, Martin ACR. Protein moonlighting in biology and medicine. 1st ed. Hoboken: Wiley Blackwell; 2017.

17. Ryu JS, Kang JH, Jung SY, et al. Production of interleukin-8 by human neutrophils stimulated with Trichomonas vaginalis. Infect Immun. 2004;72(3):1326–32. doi:10.1128/IAI.72.3.1326-1332.2004.

18. Bongiorni Galego G, Tasca T. Infinity war: Trichomonas vaginalis and interactions with host response. Microb Cell. 2023;10(5):103–16. doi:10.15698/mic2023.05.796.

19. Mercer F, Ng SH, Brown TM, et al. Neutrophils kill the parasite Trichomonas vaginalis using trogocytosis. PLoS Biol. 2018;16(2):e2003885. doi:10.1371/journal.pbio.2003885.

20. Trujillo EN, Flores BA, Romero IV, et al. Complement receptor 3 is required for maximum in vitro trogocytic killing of the parasite Trichomonas vaginalis by human neutrophil-like cells. Parasite Immunol. 2024;46(2):e13025. doi:10.1111/pim.13025.

21. Mercer F, Mukherjee SK, Ho CL, et al. Polymorphonuclear leukocytes (PMNs) use different, strain-dependent mechanisms to kill the parasite Trichomonas vaginalis. mBio. 2025;16(8):e0368024. doi:10.1128/mbio.03680-24.

22. Ibáñez-Escribano A, Nogal-Ruiz JJ, Pérez-Serrano J, et al. Sequestration of host-CD59 as potential immune evasion strategy of Trichomonas vaginalis. Acta Trop. 2015;149:1–7. doi:10.1016/j.actatropica.2015.05.003.

23. Couves EC, Gardner S, Voisin TB, et al. Structural basis for membrane attack complex inhibition by CD59. Nat Commun. 2023;14(1):1467. doi:10.1038/s41467-023-36441z.

24. Seybold DL, Contreras GP, Chang JF, et al. Recent advances in biology, host and microbe interactions of the human sexually transmitted parasite Trichomonas vaginalis. Int J Mol Sci. 2025;26(24):12015. doi:10.3390/ijms262412015.

25. Boero E, Gorham RD, Francis EA, et al. Purified complement C3b triggers phagocytosis and activation of human neutrophils via complement receptor 1. Sci Rep. 2023;13(1):598. doi:10.1038/s41598-022-27279-4.

26. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5. doi:10.1126/science.1092385.

27. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134–47. doi:10.1038/nri.2017.105.

28. 28. Ramírez-Ledesma MG, Romero-Contreras YJ, Rodríguez MC, et al. Trichomonas vaginalis triggers neutrophil extracellular traps reducing parasite integrity and growth. Parasitol Res. 2022;121(5):1355–67. doi:10.1007/s00436-022-07475-x.

29. Li L, Li X, Gong P, et al. Trichomonas vaginalis induces production of proinflammatory mediated cytokines in mouse macrophages through activation of MAPK and NF-κB pathways partially by TLR2. Front Microbiol. 2018;9:712. doi:10.3389/fmicb.2018.00712.

30. Yan L, Li Y, Yang X, et al. PI3K/AKT signaling in parasites and parasite diseases: role and therapeutic potential. Virulence. 2025;16(1):2532803. doi:10.1080/21505594.2025.2532803.

31. Nemati M, Malla N, Yadav M, et al. Humoral and T cell-mediated immune response against trichomoniasis. Parasite Immunol. 2018;40(3):e12510. doi:10.1111/pim.12510

32. 32. Provenzano D, Alderete JF. Analysis of human immunoglobulin-degrading cysteine proteinases of Trichomonas vaginalis. Infect Immun. 1995;63(9):3388–95. doi:10.1128/iai.63.9.3388-3395.1995.

33. Alderete JF, Kasmala L, Metcalfe E, et al. Phenotypic variation and diversity among Trichomonas vaginalis isolates and correlation of phenotype with trichomonal virulence determinants. Infect Immun. 1986;53(2):285–93. doi:10.1128/iai.53.2.285293.1986.

34. Khoshnan A, Alderete JF. Trichomonas vaginalis with a double-stranded RNA virus has upregulated levels of phenotypically variable immunogen mRNA. J Virol. 1994;68(6):4035–8. doi:10.1128/jvi.68.6.4035-4038.1994.

35. Twu O, de Miguel N, Lustig G, et al. Trichomonas vaginalis exosomes deliver cargo to host cells and mediate host:parasite interactions. PLoS Pathog. 2013;9(7):e1003482. doi:10.1371/journal.ppat.1003482.

36. Kochanowsky JA, Mira PM, Elikaee S, et al. Trichomonas vaginalis extracellular vesicles up-regulate and directly transfer adherence factors promoting host cell colonization. Proc Natl Acad Sci U S A. 2024;121(25):e2401159121. doi:10.1073/pnas.2401159121.

37. Huang CY, Chiu SF, Chu LJ, et al. Trichomonas vaginalis extracellular vesicles activate the NLRP3 inflammasome and TLR3-mediated inflammatory cascades in host cells. PLoS Pathog. 2025;21(6):e1013216. doi:10.1371/journal.ppat.1013216.

38. Kim J, Kim H. Recruitment and biological consequences of histone modification of H3K27me3 and H3K9me3. ILAR J. 2012;53(3–4):232–9. doi:10.1093/ilar.53.3-4.232.

39. Margarita V, Fiori PL, Rappelli P. Impact of symbiosis between Trichomonas vaginalis and Mycoplasma hominis on vaginal dysbiosis: a mini review. Front Cell Infect Microbiol. 2020;10:179. doi:10.3389/fcimb.2020.00179.

40. Graves KJ, Novak J, Muzny CA. Trichomonas vaginalis virus: current insights and emerging perspectives. Viruses. 2025;17(7):898. doi:10.3390/v17070898.

41. Margarita V, Marongiu A, Diaz N, et al. Prevalence of double-stranded RNA virus in Trichomonas vaginalis isolated in Italy and association with the symbiont Mycoplasma hominis. Parasitol Res. 2019;118(12):3565–70. doi:10.1007/s00436-019-06469-6.

42. Govender R, Mabaso N, Abbai NS. Investigating links between Trichomonas vaginalis, T. vaginalis virus, Mycoplasma hominis, and metronidazole resistance. J Infect Dev Ctries. 2024;18(10):1590–600. doi:10.3855/jidc.17592.

43. Bolumburu C, Zamora V, Muñoz-Algarra M, et al. Trichomoniasis in a tertiary hospital of Madrid, Spain (2013–2017): prevalence and pregnancy rate, coinfections, metronidazole resistance, and endosymbiosis. Parasitol Res. 2020;119(6):1915–23. doi:10.1007/s00436-020-06688-2.

44. Margarita V, Carboni G, Diaz N, et al. Patterns of antibiotic resistance of Mycoplasma hominis endosymbiont of Trichomonas vaginalis and the influence of bacterial intracellular location on drug susceptibility. J Glob Antimicrob Resist. 2023;35:210–5. doi:10.1016/j.jgar.2023.09.021.

45. Fichorova RN, Lee Y, Yamamoto HS, et al. Endobiont viruses sensed by the human host – beyond conventional antiparasitic therapy. PLoS One. 2012;7(11):e48418. doi:10.1371/journal.pone.0048418.

46. Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun. 2005;73(7):4155–60. doi:10.1128/IAI.73.7.4155-4160.2005.

47. Kissinger PJ, Gaydos CA, Seña AC, et al. Diagnosis and management of Trichomonas vaginalis: summary of evidence reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis. 2022;74(Suppl 2):S152–61. doi:10.1093/cid/ciac030.

48. 4Kissinger P, Muzny CA, Mena LA, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(11):1251–9. doi:10.1016/S1473-3099(18)30423-7.

التنزيلات

منشور

2026-12-01

إصدار

القسم

Articles

كيفية الاقتباس

Abood, S. (2026). Molecular Mechanisms of Immune Evasion and Host Manipulation by Trichomonas vaginalis: A Comprehensive Paradigm Shift. مجلة جامعة نينوى للعلوم الطبية, 2(2), 33-46. https://doi.org/10.64554/nujms.2026.2.2.4